For decades, Africa relied on medicine made halfway across the world to fight HIV. Pills shipped from India, stored in warehouses thousands of miles away, delayed by port strikes or shipping shortages. When the COVID-19 pandemic hit, those supply chains broke. People in rural clinics ran out of treatment. Families waited. Some died. That’s no longer the only story.
On May 6, 2025, something historic happened. The Global Fund shipped its first-ever batch of antiretroviral generics made in Africa. The medicine? TLD - a single pill combining tenofovir, lamivudine, and dolutegravir. It came from Universal Corporation Ltd, a company in Kenya. And it was headed to Mozambique, enough to treat over 72,000 people a year. This wasn’t a trial. It wasn’t a pilot. It was the start of a new system.
Why African-Made HIV Pills Matter
Africa carries 65% of the world’s HIV cases. Yet, for years, it imported 80% of its medicines. That meant prices were set overseas. Delivery times were unpredictable. And if a country’s budget shifted or a global crisis hit, treatment stopped. Local production changes all of that.
When a pill is made in Africa, it doesn’t need to cross oceans. It doesn’t sit in customs for weeks. It moves faster. Costs drop. And when a country can make its own medicines, it doesn’t just treat HIV - it builds a health system that can respond to future outbreaks, too.
The TLD pill is the new gold standard. It’s simpler, safer, and more effective than older regimens. It works even if someone has developed resistance to older drugs. And because it’s now made in Kenya, the price per person per year has dropped below $40 - far below the $100 it cost when India was the main supplier.
How WHO Prequalification Changed the Game
Before 2023, no African company had ever received WHO prequalification for a first-line HIV treatment. WHO prequalification isn’t just a stamp of approval. It’s a global green light. It means a medicine meets the same strict quality, safety, and effectiveness standards as those from the U.S. FDA or European regulators. Without it, organizations like the Global Fund, UNICEF, and PEPFAR couldn’t buy it.
Universal Corporation Ltd cracked the code. They invested in labs, trained technicians, passed rigorous inspections, and proved their pills worked just as well as the brand-name version. Their success didn’t happen by accident. It was built on partnerships - with the Global Fund, WHO, and African health ministries - all working to lower barriers for African manufacturers.
Now, other companies are following. By Q4 2025, at least three new African factories are expected to start producing TLD. One in South Africa. One in Nigeria. Another in Ethiopia. Each will be audited by WHO. Each will be eligible for Global Fund orders. This isn’t just about one pill. It’s about creating a pipeline.
From Pills to Injections: The Next Wave
HIV treatment is moving beyond daily pills. In October 2025, South Africa became the first African country to register a twice-yearly injectable treatment: cabotegravir long-acting (CAB LA). No more remembering to take a pill every day. Just two shots a year.
But here’s the real breakthrough: Gilead Sciences, the company that developed CAB LA, didn’t just license it to big pharma in Europe or the U.S. They signed agreements with six African manufacturers. That means the same injectable treatment will soon be made right here - in Nigeria, Kenya, South Africa - at prices 80-90% lower than the brand name.
And it’s not stopping there. Gilead is also working with the U.S. State Department and the Global Fund to supply lenacapavir - a new long-acting drug for HIV prevention - to up to two million people across Africa. They’re giving it away at no profit until generics take over. This isn’t charity. It’s a bridge. A way to get cutting-edge tools into communities while local factories scale up.
What’s Still Missing? The Scale Problem
Let’s be clear: this progress is real. But it’s still small compared to the need.
Africa needs about 15 million person-years of first-line antiretroviral treatment every year. Right now, even with the new factories, African-made ARVs will cover maybe 5% of that demand in 2026. That’s not enough. To reach 20-30% by 2030 - the current projection - we need more factories. More investment. More trained workers.
The African Union’s Pharmaceutical Manufacturing Plan for Africa (PMPA) says local production should jump from 2-3% of the continent’s needs to 40% by 2040. That sounds ambitious. It is. But it’s the only path to true health sovereignty.
Right now, regulatory systems vary wildly between countries. One country approves a drug. Another takes two years. Harmonizing those rules - so one approval works across the continent - is critical. That’s why WHO and the African Medicines Regulatory Harmonization initiative are pushing for shared standards. No more 50 different approval processes.
Beyond Pills: Diagnostics and Integration
Treatment means nothing if people don’t know they’re infected. That’s where diagnostics come in.
Codix Bio, a Nigerian company, now manufactures HIV rapid diagnostic tests under a license from SD Biosensor. This wasn’t just a tech transfer. It was a training program. Engineers learned how to build the test strips. Labs learned how to control quality. Distribution networks learned how to get them to remote clinics.
And it’s not just HIV. These same systems - the labs, the supply chains, the trained workers - can be used for malaria, TB, or even future pandemics. Building local capacity isn’t just about HIV. It’s about building a health infrastructure that lasts.
Integration is the next big challenge. Too often, HIV programs ran in isolation. Nurses trained only in HIV. Clinics didn’t share records with maternal health or diabetes programs. Now, governments are pushing to merge services. A woman coming in for an HIV test can also get her blood pressure checked. A child on ARVs can get vaccinated at the same visit. That’s more efficient. More sustainable. More human.
Who’s Paying for This?
The money isn’t coming from African governments alone. It’s a mix. The Global Fund has committed hundreds of millions to help African manufacturers meet WHO standards. Unitaid and the Gates Foundation are funding market-shaping tools - like bulk purchasing agreements - to guarantee demand. CIFF, the Children’s Investment Fund Foundation, is helping train regulatory inspectors.
This isn’t aid. It’s investment. For every dollar spent to build an African factory, experts estimate $7-$10 is saved in long-term import costs and emergency shipments. And when those factories hire local engineers, chemists, and logistics staff? They create jobs. They build expertise. They create a new economic sector.
What Comes Next?
The next step is simple: scale. More factories. More drugs. More diagnostics. More integration.
By 2027, we could see African-made ARVs covering 10% of the continent’s needs. By 2030, maybe 25%. That’s still not enough. But it’s a start. And it’s a shift. For the first time, people living with HIV in Africa aren’t just recipients of medicine made elsewhere. They’re part of a movement - one where their continent makes the tools that save their lives.
This isn’t about replacing Indian generics. It’s about adding African ones. It’s about choice. Speed. Control. And dignity.
Are African-made antiretroviral drugs as effective as those made in India or the U.S.?
Yes. Every African-made antiretroviral drug approved for Global Fund procurement must pass WHO prequalification, which requires proof of quality, safety, and effectiveness equal to the strictest global standards. The TLD pill made in Kenya, for example, was tested in clinical trials across multiple African countries and matched the performance of brand-name and Indian-made versions. Regulatory bodies don’t lower standards for local production - they raise the bar.
Why did it take so long for African manufacturers to produce WHO-prequalified ARVs?
It wasn’t a lack of skill - it was a lack of support. Most African pharmaceutical companies lacked funding to upgrade labs, hire regulatory experts, or navigate the complex WHO prequalification process. There was also little guaranteed demand. Without orders from large buyers like the Global Fund, factories couldn’t justify the investment. The breakthrough came when donors shifted from buying only from India to actively funding African manufacturers to meet international standards - creating a market where none existed before.
Can African countries really produce enough ARVs to meet their own needs?
Currently, no - but they’re on track. Africa needs 15 million person-years of first-line ARV treatment annually. Today, African manufacturers supply less than 5%. But with new factories opening in Kenya, Nigeria, South Africa, and Ethiopia by late 2025, that number could rise to 10-15% by 2027. Reaching 30% by 2030 is realistic if funding continues and regulatory systems harmonize across the continent. It’s not about replacing India overnight - it’s about building a parallel, sustainable system.
What role do international donors play in this shift?
Donors aren’t just giving money - they’re changing how the market works. The Global Fund now prioritizes buying African-made ARVs. Unitaid funds technical training. The Gates Foundation supports regulatory capacity. These aren’t charity grants - they’re market-shaping investments. By guaranteeing demand, they give African manufacturers the confidence to invest in factories, hire staff, and upgrade equipment. Without this, local production would remain too risky to scale.
How does this affect people living with HIV in rural areas?
It changes everything. When pills are made locally, delivery times shrink from months to weeks. Stockouts become rare. Clinics get consistent supplies. Longer-acting treatments like the twice-yearly injection mean fewer clinic visits. And when diagnostics are made locally - like the HIV rapid tests from Nigeria - testing becomes faster and cheaper. People aren’t just getting treatment. They’re getting reliable, dignified care.